Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXSubjects who have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)Xx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia within the past 28 days; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXPrior bisphosphonate use is permittedXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia are NOT allowed; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXInitiation of bisphosphonate/denosumab therapy during protocol treatment; patients on stable doses of bisphosphonates or denosumab which have been started no less than 4 weeks prior to treatment start may continue on this medication; NOTE: initiation of bisphosphonate/denosumab therapy will be allowed for the treatment of osteoporosis or prevention of skeletal-related events (SRE) during protocol treatmentXx_NEWLINE_xXSymptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapyXx_NEWLINE_xXBisphosphonates will not be allowed on the study while the participant is receiving sotatercept; prior bisphosphonate use is allowedXx_NEWLINE_xXUncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy;Xx_NEWLINE_xXUncontrolled tumor-related pain, or uncontrolled hypercalcemia or clinically significant (symptomatic) hypercalcemiaXx_NEWLINE_xXPatients on bisphosphonates may continue receiving bisphosphonate therapy during study treatmentXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXHave initiated treatment with bisphosphonates less than 30 days prior to study registration; concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to study registrationXx_NEWLINE_xXPatients on bisphosphonates may continue receiving bisphosphonate therapy during study; patients wanting to initiate bisphosphonate therapy may do soXx_NEWLINE_xXSubjects on bisphosphonate therapy must be on a stable dose and must have started therapy > 4 weeks prior to protocol therapy.Xx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXUncontrolled hypercalcemia (ionized calcium >1.5 millimoles per liter [mmol/L], calcium >12 milligrams per deciliter [mg/dL], or corrected calcium greater than the upper limit of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapyXx_NEWLINE_xXInitiation of bisphosphonate/denosumab therapy during the study; subjects on stable doses of bisphosphonates or the tumor necrosis factor receptor superfamily member 11a, subfamily L (RANK-L) inhibitor, denosumab, which have been started no less than 4 weeks prior to registration, may continue on this medicationXx_NEWLINE_xXPatients on bisphosphonates may continue receiving bisphosphonate therapy during study treatmentXx_NEWLINE_xXParticipants on bisphosphonates may continue receiving bisphosphonate therapy during study treatmentXx_NEWLINE_xXBisphosphonate therapy (osteoporosis or symptomatic hypercalcaemia) or denosumab (osteoporosis) prior to study drugXx_NEWLINE_xXHistory of hypercalcemiaXx_NEWLINE_xXGENERAL: Bisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.Xx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients with bone metastases who have initiated denosumab or bisphosphonate therapy within 28 days prior to cycle 1 day 1Xx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients with bone metastases who have initiated denosumab or bisphosphonate therapy within 28 days prior to cycle 1 day 1Xx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients with bone metastases who have initiated denosumab or bisphosphonate therapy within 28 days prior to cycle 1 day 1Xx_NEWLINE_xXInitiating bisphosphonate, or RANKL antibody therapy or adjusting the dose/regimen within 30 days prior to cycle 1 day 1 is prohibited; patients on a stable bisphosphonate regimen are eligible and may continueXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., osteoporosis) is allowedXx_NEWLINE_xXUncontrolled or symptomatic hypercalcemiaXx_NEWLINE_xXAdministration of other prior anticancer therapies within 4 weeks of enrollment, except ongoing administration of a bisphosphonate drug or denosumab as treatment for bone metastasisXx_NEWLINE_xXPatients receiving bisphosphonate or denosumab therapy must have been on stable doses for at least 4 weeks prior to screeningXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed.Xx_NEWLINE_xXParticipants on bisphosphonates may continue receiving bisphosphonate therapy during study treatmentXx_NEWLINE_xXUse of bisphosphonate therapy for osteoporosis will be allowed if started prior to study enrollmentXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia a) Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXBisphosphonate or denosumab dosage must have been stable for at least 4 weeks before day 1 for patients receiving these therapies.Xx_NEWLINE_xXUncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or calcium[Ca] > 12 mg/dL or corrected serum calcium > ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab\r\n* Subjects who are receiving bisphosphonate therapy or denosumab specifically to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible\r\n* Subjects who are receiving denosumab prior to enrollment must be willing and eligible to receive a bisphosphonate instead while in the studyXx_NEWLINE_xXThe use of a RANKL inhibitor (denosumab) must be discontinued during the study; bisphosphonate therapy is permittedXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXHas received prior bisphosphonate therapyXx_NEWLINE_xXTreatment within the past two years with a bisphosphonate or a Rank ligand inhibitorXx_NEWLINE_xXHypercalcemiaXx_NEWLINE_xXConcurrent bisphosphonate therapy is not excluded, however patients should not start bisphosphonate therapy while on this study; those patients already receiving bisphosphonate therapy should continue at the same dosing and schedule as prior to study entryXx_NEWLINE_xXExcept GnRH analogue therapy, any other therapies for prostate cancer (excluding bisphosphonate and denosumab) must be discontinued 3 weeks before the first dose of study drugsXx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXConcurrent bisphosphonate or receptor activator of nuclear factor kappa-B (RANK)-ligand directed therapy for prevention of skeletal related events or treatment of osteoporosis is allowedXx_NEWLINE_xXHave initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)Xx_NEWLINE_xXTotal calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)Xx_NEWLINE_xXInitiation or discontinuation of bisphosponate use within past 14 days\r\n* Continuation of use is allowed but patients must continue bisphosphonate throughout the treatment and follow up period until disease progressionXx_NEWLINE_xXTotal calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)Xx_NEWLINE_xXHypercalcemiaXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia\r\n* Note: use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia (use of bisphosphonate therapy for other reasons [e.g., osteoporosis] is allowed.)Xx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXInitiating bisphosphonate or denosumab therapy or adjusting dose/regimen within 3 months prior to Cycle 1 Day 1. Subjects on a stable bisphosphonate or denosumab therapy are eligible and may continue.Xx_NEWLINE_xXActive intravenous (IV) bisphosphonate use in the last 3 monthsXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment, denosumab, or similar agents areare eligible to participate and may continue this treatment; patients with prostate cancer may continue luteinizing hormone-releasing hormone (LHRH) agonists or antagonistsXx_NEWLINE_xXTREATMENT: Patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment, denosumab, or similar agents are eligible to participate and may continue this treatment; patients with prostate cancer may continue LHRH agonists or antagonistsXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXIV bisphosphonate and denosumab for bony metastatic disease will be allowedXx_NEWLINE_xXCo-administration of enzyme-inducing antiepileptic drugs, rifampin, rifabutin, rifapentine, or St. John’s wort is not permitted; concurrent bisphosphonate therapy is allowed if it was started before study entry and is maintained at recommended dosing intervals; bisphosphonate therapy may not be initiated after study entryXx_NEWLINE_xXTotal calcium (corrected for serum albumin) within normal limits (ongoing requirement for bisphosphonate to control malignant hypercalcemia is not allowed but prophylactic use of bisphosphonate to prevent skeletal complication of bone metastasis is allowed)Xx_NEWLINE_xXPatient may have received or plan to receive concurrent bone targeting agents that do not have an effect on PSA (e.g. denosumab or bisphosphonate)Xx_NEWLINE_xXParticipants receiving bisphosphonate or denosumab therapy must have been on a stable dose for at least 4 weeksXx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXConcurrent use of bisphosphonates is not permitted; however, prior bisphosphonates or once-a-year intravenous bisphosphonate given for the treatment of osteoporosis is permittedXx_NEWLINE_xXA minimum of 28 days beyond initiation of bisphosphonate or denosumab therapyXx_NEWLINE_xXParticipants receiving bone resorptive therapy (including, but not limited to bisphosphonate or receptor activator of nuclear factor kappa-? ligand inhibitor) must be on stable doses for ?4 weeks prior to first dose of study therapyXx_NEWLINE_xXHigh levels of calcium requiring bisphosphonate therapy or denosumab.Xx_NEWLINE_xXIntravenous (IV) bisphosphonate and denosumab for bony metastatic disease will be allowedXx_NEWLINE_xXParticipants receiving bone resorptive therapy (including but not limited to bisphosphonate or RANK-L inhibitor) must have therapy initiated at least 2 weeks prior to treatment allocation.Xx_NEWLINE_xXIf receiving bone resorptive therapy (including but not limited to bisphosphonate or RANK-L inhibitor) must have therapy initiated at least 2 weeks prior to randomization.Xx_NEWLINE_xXSubjects must be on therapy with bisphosphonate and denosumab. and are required to have been on such therapy for at least 1 month before start of study treatment.Xx_NEWLINE_xXUncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumabXx_NEWLINE_xXTreatment with bisphosphonate or denosumab within 12 weeks before randomisation.Xx_NEWLINE_xXUncontrolled or symptomatic hypercalcemiaXx_NEWLINE_xXPrior or ongoing bisphosphonate (e.g,. zoledronic acid) or RANKL inhibitor (e.g. denosumab) use is NOT allowed except when used solely for osteoporosis and strictly per guidelines for that indication. Bisphosphonate or RANKL inhibitor cannot be initiated for any indication during protocol specified therapy without consent of the sponsor-investigator of the study.Xx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXNo current anti-myeloma bisphosphonate therapy (however, prior bisphosphonates and/or bisphosphonate therapy due to osteoporosis is allowed)Xx_NEWLINE_xXPatients may have initiated bisphosphonate therapy prior to start of protocol therapy; bisphosphonate therapy may continue during protocol treatment; such patients will have bone lesions considered evaluable for progressionXx_NEWLINE_xXTotal calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)Xx_NEWLINE_xXCurrent or previous chemotherapy or bisphosphonate therapy is permissibleXx_NEWLINE_xXUncontrolled hypercalcemia (greater than [>] 1.5 millimoles per liter [mmol/L] ionized calcium or Ca > 12 milligrams per deciliter [mg/dL] or corrected serum calcium > upper limits of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumabXx_NEWLINE_xXBisphosphonate (e.g. zoledronic acid) and receptor activator of nuclear transcription factor kappa-B (NF-kappaB) ligand (RANKL) inhibitor (e.g. denosumab) use for bone metastasis is permittedXx_NEWLINE_xXUncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab General Medical Exclusion Criteria:Xx_NEWLINE_xXPatient can be receiving bisphosphonate therapy per the treating oncologist's discretion.Xx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemia\r\n* Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXUncontrolled or symptomatic hypercalcemiaXx_NEWLINE_xXPatients receiving bisphosphonate therapy or denosumab must have been on a stable dose for at least 4 weeks prior to enrollmentXx_NEWLINE_xXHistory of hypercalcemiaXx_NEWLINE_xXPatients may have initiated bisphosphonate therapy prior to start of protocol therapy; bisphosphonate therapy may continue during protocol treatment; such patients will have bone lesions considered evaluable for progressionXx_NEWLINE_xXPatients receiving bisphosphonate therapy must have been on stable doses for at least 4 weeks with stable symptoms prior to the first infusion with ipilimumabXx_NEWLINE_xXBisphosphonate or receptor activated of nuclear factor kappa-B (RANK) ligand inhibitor therapy for bone metastases is allowed; prophylactic use of bisphosphonates in subjects without bone disease, except for the treatment of osteoporosis, is not permittedXx_NEWLINE_xXPatients may receive a bisphosphonate.Xx_NEWLINE_xXTotal calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed; the use of denosumab [Xgeva] is permitted)Xx_NEWLINE_xXPatients may not initiate bisphosphonate or denosumab therapy while receiving treatment on this study; patients who have begun receiving bisphosphonate or denosumab therapy prior to registration may continue at the same intervals used prior to study registrationXx_NEWLINE_xXPatients may not initiate bisphosphonate therapy while receiving treatment on this study; patients who have begun receiving bisphosphonate therapy prior to registration may continue at the same intervals used prior to study registrationXx_NEWLINE_xXPatients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowedXx_NEWLINE_xXPrior or current IV bisphosphonate administrationXx_NEWLINE_xXUncontrolled hypercalcemia ( ?1.5 mmol/L ionized calcium or Ca > 12 mg/dL) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab (patients receiving bisphosphonate therapy or denosumab to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible, though patients receiving denosumab must be willing and eligible to receive bisphosphonates instead)Xx_NEWLINE_xXParticipants receiving bisphosphonate or denosumab therapy must be on stable doses for at least 4 weeks before start of study therapyXx_NEWLINE_xXSubjects currently on a bisphosphonate or denosumab are eligible for study therapyXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemiaXx_NEWLINE_xXLack of treatment with a bisphosphonate or denosumabXx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemiaXx_NEWLINE_xXLack of treatment with a bisphosphonate or denosumabXx_NEWLINE_xXInitiation of bisphosphonate therapy < 4 weeks prior to first dose of KPT-330; patients receiving bisphosphonate or denosumab therapy must be on stable doses for at least 4 weeks prior to first dose of KPT-330Xx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemiaXx_NEWLINE_xXLack of treatment with a bisphosphonate or denosumabXx_NEWLINE_xXBisphosphonate therapy for symptomatic hypercalcemiaXx_NEWLINE_xXLack of treatment with a bisphosphonate or denosumabXx_NEWLINE_xXSymptomatic hypercalcemia requiring continued use of bisphosphonate therapyXx_NEWLINE_xXTotal calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)Xx_NEWLINE_xXSubject receiving bisphosphonate or denosumab therapy must have been on stable doses for at least 4 weeks prior to Day 1Xx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXSymptomatic hypercalcemiaXx_NEWLINE_xXBisphosphonate therapy currently or within the past 12 monthsXx_NEWLINE_xXTotal calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)Xx_NEWLINE_xXSymptomatic hypercalcemia requiring continued use of bisphosphonate therapy. Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible.Xx_NEWLINE_xXSymptomatic hypercalcemia requiring continued use of bisphosphonate therapyXx_NEWLINE_xXThe patient has hypercalcemia.Xx_NEWLINE_xXThe patient has hypercalcemia.Xx_NEWLINE_xXConcurrent bisphosphonate treatmentXx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXUncontrolled hypercalcemiaXx_NEWLINE_xXNo radiation therapy to targeted (most painful) lesion in the past two weeks Bisphosphonate intake should remain stable throughout the study duration.Xx_NEWLINE_xXParticipants on bisphosphonates/denosumab may continue receiving bisphosphonate therapy during study treatmentXx_NEWLINE_xXSymptomatic hypercalcemia requiring bisphosphonate or denosumab therapyXx_NEWLINE_xXPatients undergoing bisphosphonate therapy are allowedXx_NEWLINE_xXUncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapyXx_NEWLINE_xXMore than 1 previous dose of IV bisphosphonate administrationXx_NEWLINE_xXNo prior history of bisphosphonate or denosumab use in the past 12 monthsXx_NEWLINE_xXPatients with current or previous bisphosphonate therapyXx_NEWLINE_xXPrevious treatment with denosumab or use of bisphosphonate within 3 months of start of studyXx_NEWLINE_xXKnown hypercalcemiaXx_NEWLINE_xXUncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab (bisphosphonate use for prevention of skeletal events allowed)Xx_NEWLINE_xXPatients on stable doses of bisphosphonates or the receptor activator of RANK-L inhibitor, denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication, however patients are not allowed to initiate bisphosphonate/denosumab therapy during the studyXx_NEWLINE_xXPatients who have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228) are ineligible; concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)Xx_NEWLINE_xXUncontrolled or symptomatic hypercalcemiaXx_NEWLINE_xXPatients currently using oral bisphosphonate therapyXx_NEWLINE_xXUncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > upper limit of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy; patients who are receiving denosumab must discontinue denosumab use and replace it with a bisphosphonate instead while on study; patients receiving a bisphosphonate for skeletal metastases are not excluded and can continue treatmentXx_NEWLINE_xX